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Several homeodomain (HD) proteins are critical for skeletal
patterning and responddirectly toBMP2as an early step inbone
formation. RUNX2, the earliest transcription factor proven
essential for commitment to osteoblastogenesis, is also
expressed in response to BMP2. However, there is a gap in our
knowledge of the regulatory cascade fromBMP2 signaling to the
onset of osteogenesis.Herewe show that BMP2 inducesDLX3, a
homeodomain protein that activates Runx2 gene transcription.
Small interfering RNA knockdown studies in osteoblasts vali-
date that DLX3 is a potent regulator of Runx2. Furthermore in
Runx2 null cells, DLX3 forced expression suffices to induce
transcription of Runx2, osteocalcin, and alkaline phosphatase
genes, thus definingDLX3 as an osteogenic regulator independ-
ent ofRUNX2.Our studies further show regulation of theRunx2
gene by several homeodomain proteins: MSX2 and CDP/cut
repress whereas DLX3 and DLX5 activate endogenous Runx2
expression and promoter activity in non-osseous cells and
osteoblasts. These HD proteins exhibit distinct temporal
expression profiles during osteoblast differentiation as well as
selective association with Runx2 chromatin that is related to
Runx2 transcriptional activity and recruitment of RNA poly-
merase II. Runx2 promoter mutagenesis shows that multiple
HD elements control expression of Runx2 in relation to the
stages of osteoblast maturation. Our studies establish mech-
anisms for commitment to the osteogenic lineage directly
through BMP2 induction of HD proteins DLX3 and DLX5
that activate Runx2, thus delineating a transcriptional regu-
latory pathway mediating osteoblast differentiation. We pro-
pose that the three homeodomain proteins MSX2, DLX3, and
DLX5 provide a key series of molecular switches that regulate
expression of Runx2 throughout bone formation.
Skeletal development is a complex process wherebymultiple
signaling pathways converge to induce formation of bone struc-
tures. The BMP2/4/7 4 members of the transforming growth
factor- superfamily of signaling polypeptides are essential for
commitment and differentiation of mesenchymal cells to the
osteoblast lineage for bone tissue formation. The BMP signal is
transduced through the binding to their heterodimeric type I
and type II serine/threonine kinase receptors with formation of
activated Smad complexes that are translocated to the nucleus
to regulate target genes (1). BMP2 target genes include a cohort
of transcription factors with specialized activities for induction
of cell type-specific lineages. Among the BMP2 target genes are
transcription factors that have essential roles in skeletal devel-
opment, including several homeodomain proteins, the bone-
related runt homology domain factor RUNX2 (CBFA1/AML3),
and an SP1 family member, OSTERIX (2–4). BMP/transform-
ing growth factor- intracellular Smads will also form co-reg-
ulatory complexes with transcription factors to regulate target
genes. The potent osteogenic effects of BMPs are mediated in
part by formation of RUNX2-SMAD complexes for phenotypic
gene induction (5, 6).
RUNX2 is essential for development of the osteoblast phe-
notype (2, 7, 8). The protein is expressed in the early mesen-
chyme of developing skeletal tissues (embryonic age E9.5)
(9–12), and null mouse models have clearly established that
RUNX2 is required for osteoblast differentiation and bone for-
mation at later stages of embryonic development. In undiffer-
entiated mouse embryo fibroblasts, RUNX2 is repressed by the
chondrogenic homeodomain protein NKX3.2 (13, 14) provid-
ing amechanism for lineage switching and allowing themesen-
chymal cells to enter the chondrogenic lineage under appropri-
ate conditions. RUNX2 becomes up-regulated in hypertrophic
chondrocytes and the differentiated osteoblast (15–17). A com-
pelling question to be addressed relates to tissue-specific regu-
latory sequences that support Runx2 transcription for osteo-
genic lineage direction upon BMP2 induction of osteogenesis.
Given the early response of RUNX2 and many homeodomain
proteins to the BMP osteogenic signal as identified in several
microarray gene profiling studies (18, 19), a clear understand-
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ing of how the activity of multiple HD proteins and RUNX2 are
coordinated for control of the onset of osteogenesis requires
further study.
Homeodomain proteins play a key role in skeletal develop-
ment. For example, MSX1 and MSX2 members of the Msh
family of homeobox genes are classical repressor proteins that
are expressed in neural crest cells and limb tissue to regulate
skeletal patterning and the number of osteoprogenitor cells.
Msx1 andMsx2 null double mutant phenotypes exhibit severe
craniofacial abnormalities, skull ossification, and limb defects
(20–23). MSX2 inhibits chondrogenesis and is critical for reg-
ulation of osteoblast differentiation (24–27). The mammalian
homologues of Drosophila distal-less (DLX) proteins are
among the homeodomain proteins that also function in speci-
fication of skeletal structures (3, 28, 29). DLX2 and DLX3 con-
tribute to craniofacial development but with distinct temporal
and spatial patterns of expression (30, 31). DLX2 also has an
important role in mesenchymal condensation (32). DLX5 and
DLX6 are essential for development of jaw, axial, and appendic-
ular bone (29). Several in vitro studies demonstrate that DLX5,
an inducer of mesoderm differentiation, is up-regulated during
osteoblast differentiation (33) and is competent to induce
chondrocyte and osteoblast differentiation (34, 35). Further-
moreDLX5 is required for BMP2-mediated induction of osteo-
genesis in C2C12 myogenic cells concomitant with increased
Runx2 expression (36, 37). Although the Dlx3 null mouse is
embryonic lethal prior to skeletal development due to placental
failure (38, 39), recent studies showed thatDLX3 is expressed in
periosteum, osteoblasts, and chondrocytes of the developing
limb and in osteogenic lineage cells (40, 41). In this study we
have therefore addressed a mechanism for activation and
regulation of the RUNX2 transcription factor by DLX3 and
in relation to other homeodomain proteins expressed during
osteoblastogenesis.
Here we provide evidence for molecular switches that are
operative on the bone-related P1 Runx2 promoter in normal
diploid osteoblasts. These switches are mediated by the
MSX2, DLX3, and DLX5 homeodomain proteins and sup-
port Runx2 repression and activation to regulate osteoblast
differentiation and bone formation. Recent studies have
identified regulatory sequences in the proximal promoter
contributing to enhanced transcriptional control of endoge-
nous Runx2 gene expression in response to WNT- catenin
signaling (42), DLX5 (37), and AP-1 factors (43, 44) as well as
autoregulation by RUNX2 itself (45). The present studies
identify classical homeodomain regulatory sequences in the
proximal promoter that are either activated by DLX3 and
DLX5 or repressed by MSX2 and CDP/cut. Importantly
these proteins are recruited to the Runx2 promoter at differ-
ent stages of osteoblastogenesis in relation to Runx2 tran-
scription. DLX3, DLX5, and RUNX2 are coordinately
recruited with significant increases in RNA POL II (Runx2
transcription). However, DLX3 association is early and tran-
sient, whereas the DLX5 functional associations with the
Runx2 gene promoter are sustained in mature osteoblasts.
By overexpression and knockdown studies, the functional
effects of MSX2, DLX3, and DLX5 on Runx2 promoter activ-
ity and endogenous gene expression in osseous and non-
osseous cells are established. We also show that DLX3 is a
potent activator of Runx2 transcription in non-osseous cells
and that DLX3 and DLX5 can activate RUNX2 target genes
in Runx2 null cells. These findings support mechanisms by
which BMP2 allows commitment to the osteogenic lineage
through induction of both HD and RUNX2 proteins as early
response genes.
MATERIALS ANDMETHODS
Cell Cultures—C3H10T1/2 and NIH3T3 cells were main-
tained in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% fetal bovine serum (Atlanta Biologi-
cals, Atlanta, GA). MC3T3 cells were maintained in -MEM
supplemented with 10% fetal bovine serum. Primary rat osteo-
blast cells were isolated from calvaria of fetal rats at day 21 of
gestation by three sequential digestions with collagenase P (2
mg/ml; Roche Applied Science) at 37 °C and 0.25% trypsin
(Invitrogen) treatment as detailed previously (46). Cells from
the third digestion were plated at a density of 4  105 cells/
100-mm dish and fed every 2nd day with minimal essential
medium (MEM; Invitrogen) supplemented with 10% fetal
bovine serum. The same procedure was used for isolation of
cells from calvaria of Runx2 null mice (2, 47). A Runx2/ sta-
ble cell line was derived by telomerase reverse transcriptase
immortalization (48). Establishment and characterization of a
Runx2/ stable cell line is described previously (62). In both
MC3T3 and primary cells, differentiation was induced at
monolayer confluency by addition of 50 g of ascorbic acid/ml
and 10 mM -glycerol phosphate to the medium with every
feeding.
Transient Transfections and Luciferase Reporter Assays—
Transient transfections were performed in 6-well plates at
50–70% confluence using 5 l of FuGENE 6 transfection rea-
gent (Roche Applied Science) and 0.5–1 g of promoter
reporter DNA/well in accordance with themanufacturer’s pro-
tocol. For MSX2, DLX3, and DLX5 expression, a variable
amount (50, 100, and 200 ng) of the respective expression clone
in pcDNA plasmid backbone was transfected into each well
unless otherwise noted. As a control, 100–400 ng of empty
pcDNA expression vector was transfected into each well as
appropriate. To monitor transfection efficiency, transfections
included 25 ng of a promoterless Renilla luciferase reporter
construct/well. For Runx2 promoter-reporter assays, transfec-
tions included 0.5 g of either a Runx2 0.6-kb promoter-lucif-
erase construct or the deletion mutant of 0.6-kb Runx2 pro-
moter construct. The promoterless pGL3 luciferase construct
(0.5g) was used as a control to examine the background lucif-
erase activity. All results were normalized to activity of the
pGL3 empty vector (Promega, Madison, WI).
Cells transfected with Runx2 promoter-luciferase reporter
constructs were harvested 24–36 h and in some cases 72 h after
transfection, and each well was lysed at room temperature for
20 min in the presence of 0.3 ml of Passive Lysis Buffer (Pro-
mega). Firefly luciferase activity was quantitated in a luminom-
eter using a 12-s measurement immediately after addition of
10–20 l of cell lysate to 100 l of substrate (Promega Lucifer-
ase Assay System). All results were normalized to the luciferase
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activity resulting from transfection of the promoterless PGL3
luciferase construct (Promega).
RNA Isolation and Q-PCR Analysis—RNAwas isolated from
cultures of MC3T3, NIH3T3, C3H10T1/2, and Runx2/ cells
usingTRIzol reagent (Invitrogen) according to themanufactur-
er’s protocol. After purification, 5 g of total RNA was DNase
I-treated using aDNA-free RNAcolumnpurification kit (Zymo
Research, Orange, CA). RNA (1 g) was then reverse tran-
scribed using oligo(dT) primers and the SuperScript first
strand synthesis kit (Invitrogen) according to the manufac-
turer’s protocol. Gene expression was assessed by quantita-
tive real time PCR performed using 2 SYBR Green Master
Mix (Eurogentec) and a two-step cycling protocol (anneal
and elongate at 60 °C, denature at 94 °C). Specificity of prim-
ers was verified by dissociation/melting curve for the ampli-
cons when using SYBR Green as a detector. Primers used for
PCRs are listed in Table 1.
Western Blotting—For the detection of MSX2, DLX3, DLX5,
RUNX2, and Actin proteins, each well of a 6-well plate was
lysed in 400 l of lysis buffer containing 2% SDS, 10 mM dithi-
othreitol, 10% glycerol, 12% urea, 10 mM Tris-HCl (pH 7.5), 1
mM phenylmethylsulfonyl fluoride, 1 protease inhibitor mix-
ture (RocheApplied Science), 25MMG132proteasome inhib-
itor and boiled for 5 min. Proteins were then quantified using
Bradford reagent (Pierce) and taking spectrophotometric read-
ings at 590 nm. Concentrations were estimated against a stand-
ard curve generated using bovine serum albumin. Total protein
(20 g) was subjected to electrophoresis in a denaturing 10%
polyacrylamide gel containing 10% SDS. Proteins were then
transferred onto Immobilon-P membranes (Millipore, Bil-
lerica, MA) using a semidry transfer apparatus. Membranes
were blocked in phosphate-buffered saline, 0.1%Tween 20 con-
taining 2% nonfat powdered milk (Bio-Rad). Proteins were
detected by incubating with antibodies at a concentration of 50
ng/ml in blocking solution. Antibodies used in this study were
purchased from Santa Cruz Biotechnology, Santa Cruz, CA,
except for a RUNX2 mouse monoclonal antibody that was a
generous gift from Drs. Yoshi Ito and Kosei Ito, National Uni-
versity, Singapore (Research & Development Antibodies, Beni-
cia, CA). Anti-Actin goat polyclonal antibody (I-19) was from
Santa Cruz Biotechnology. Primary antibodies were detected
with goat anti-mouse secondary antibody conjugated to horse-
radish peroxidase. Secondary antibodies were detected using
Western Lightning chemiluminescence reagent (PerkinElmer
Life Sciences).
Chromatin Immunoprecipitation (ChIP) Assays—To cross-
link proteins to DNA, rat calvarial osteoblast and preosteoblast
MC3T3 cells were incubated for 15min at room temperature in
12.5 ml of serum-free media containing 1% formaldehyde. A
final concentration of 0.125 M glycine was added to the 1%
formaldehyde-media solution for neutralization for another 15
min. The cells were collected in phosphate-buffered saline (1)
after plates were washed twice with ice-cold phosphate-buff-
ered saline. Cells were then resuspended in SDS lysis buffer (1%
SDS, 50mMTris, pH 8.1, 10mMEDTA) containing 1mM phen-
ylmethylsulfonyl fluoride (Sigma), 25 M MG-132 (Calbio-
TABLE 1
Primers for PCR assays
Primers for real time PCR assays
Homeodomain primers (mouse)
Dlx2 Forward primer, 5-AGT TCG TCT CCG GTC AAC AA-3
Reverse primer, 5-TTT CAG GCT CAA GGT CTT CC-3
Dlx3 Forward primer, 5-GTA CCG GGA GCA GCC TTT-3
Reverse primer, 5-CTT CCG GCT CCT CTT TCA C-3
Dlx5 Forward primer, 5-GCC CCT ACC ACC AGT ACG-3
Reverse primer, 5-TCA CCA TCC TCA CCT CTG G-3
Msx2 Forward primer, 5-ATA CAG GAG CCC GGC AGA TA-3
Reverse primer, 5-CGG TTG GTC TTG TGT TTC CT-3
CDP-cut Forward primer, 5-GAG GGT CAA AGA GGT GCT GA-3
Reverse primer, 5-CCA AAA TGG TCT CCC CAA AT-3
Bone marker primers (mouse)
Bone Sialoprotein Forward primer, 5-GCA CTC CAA CTG CCC AAG A-3
Reverse primer, 5-TTT TGG AGC CCT GCT TTC TG-3
Alkaline phosphatase Forward primer, 5-TTG TGC CAG AGA AAG AGA GAG A-3
Reverse primer, 5-GTT TCA GGG CAT TTT TCA AGG T-3
Runx2 Forward primer, 5-CGG CCC TCC CTG AAC TCT-3
Reverse primer, 5-TGC CTG CCT GGG ATC TGT A-3
Osteocalcin Forward primer, 5-CTG ACA AAG CCT TCA TGT CCA A-3
Reverse primer, 5-GCG GGC GAG TCT GTT CAC TA-3
Primers for RT-PCR assays
Homeodomain primers (mouse)
Dlx2 Forward primer, 5- GGC ACC AGT TCG TCT CCG GCT-3
Reverse primer, 5-CGC CGA AGT CCC AGG ATG CTG-3
Dlx3 Forward primer, 5-TCT GGT TCC AGA ACC GCC GCT-3
Reverse primer, 5-CAG TAC ACA GCC CCA GGG TTA-3
Dlx5 Forward primer, 5-CCA CCG ATT CTG ACT ACT AC-3
Reverse primer, 5-TAC CAT TCA CCA TCC TCA CC-3
Msx2 Forward primer, 5-GTC ATG GCT TCT CCG ACT AA-3
Reverse primer, 5-ATT TTC CGA CTT GAC CGA GG-3
CDP-cut Forward primer, 5-TCT CCG ACC TCC TTG CCC G-3
Reverse primer, 5-G CCC CCA GCC ACA ACA CCA-3
Bone marker primers (mouse)
Alkaline phosphatase Forward primer, 5-TTG TGC CAG AGA AAG AGA GAG A-3
Reverse primer, 5-GTT TCA GGG CAT TTT TCA AGG T-3
Osteocalcin Forward primer, 5-CCA GTC CCA CAC AGC AGC CTT-3
Reverse primer, 5-AAA GCC GAG CTG CCA GAG TT-3
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chem/Sigma), and 1 protease inhibitor (Roche Applied Sci-
ence). To isolate the nuclei, cells were homogenized in a
Dounce homogenizer followed by centrifugation at 1,100 rpm
at 4 °C. The nuclei pellets were resuspended in 500 l (500
l/100-mm plate) of lysis buffer. Samples were sonicated to
shear DNA into 0.2–0.6-kb fragments. Cellular debris were
removed by centrifugation at 14,000 rpm for 15min at 4 °C, and
resulting chromatin-containing solutions were distributed into
multiple 100-l aliquots (with equal protein concentrations)
that were used as the starting material of all subsequent steps.
900 l of Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2
mMEDTA, 16.7mMTris-HCl, pH8.1, 167mMNaCl) was added
to each immunoprecipitate (100 l)
with 1 mM phenylmethylsulfonyl
fluoride, 25 M MG-132, and 1
protease inhibitor.
Chromatin aliquots were pre-
clearedwith 60l of a 25% (v/v) sus-
pension of protein A/G beads. Sam-
ples were used directly for the IP
reaction with 3 g of specific anti-
body of interest (anti-RUNX2, anti-
MSX2, anti-DLX5, anti-DLX3, anti-
POL II), and a negative control with
normal rabbit/mouse IgG was used.
ChIP reactions were allowed to pro-
ceed for 4 h to overnight at 4 °C on a
rotating wheel. Immune complexes
were mixed with 60 l of 25% (v/v)
precoated protein A/G-agarose sus-
pension (SantaCruzBiotechnology)
followed by incubation for 2 h at
4 °C on a rotating wheel. Beads were
collected by brief centrifugation,
and the immune complexes were
washed with low salt (150mMNaCl,
0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl, pH 8.1),
high salt (500 mM NaCl, 0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20
mM Tris-HCl, pH 8.1), LiCl salt
(0.25 M LiCl, 1% Nonidet P-40, 1%
sodium deoxycholate, 1 mM EDTA,
10 mM Tris-HCl, pH 8.1), and Tris-
EDTA buffer sequentially at 4 °C.
The immune complexes were
eluted twice by adding 150 l of
freshly prepared elution buffer (100
mMNaHCO3, 1% SDS). After rever-
sal of cross-links at 68 °C overnight,
the eluate was treated with 100
g/ml proteinase K followed by
phenol-chloroform extraction and
ethanol precipitation using 5 g of
glycogen as carrier. An aliquot
(2–3 l) of each sample was
assayed using quantitative PCR for
the presence of specific DNA frag-
ments using primers that span the proximal Runx2 pro-
moter. The rat Runx2 promoter primers are: forward
5-CTC CAG TAA TAG TGC TTG CAA AAA AT-3 and
reverse 5-GCG AAT GAA GCA TTC ACA CAA-3. The
mouse Runx2 promoter primers are: forward 5-TGG TAG
GCA GTC CCA CTT TAC-3 and reverse 5-GGC TGG
TAGTGACCTGCAGAG-3.The immunoprecipitate sam-
ples were analyzed by two methods: 1) hot PCR in which
regular amplification was performed with 2.5 Ci of
[-32P]dCTP label or 2) quantitative real time PCR that was
carried out using 2 SYBR Green Master Mix (Eurogentec)
and a two-stage cycling protocol (60 °C annealing and exten-
FIGURE1.Expressionprofile of osteogenicmarkers andhomeodomainproteinsduring the initial 24hof
BMP2-treated C2C12 cells. Premyogenic C2C12 cells were treated with 100 ng/ml BMP2 for 24 h. Total RNA
was isolated at different time points (0, 1, 2, 4, 6, 8, 12, 16, 20, and 24 h). 5g of total DNase I-treated RNAwas
reverse transcribed with oligo(dT) primer and amplified by gene-specific primers by RT-qPCR to quantitate
gene expression. A, bone phenotype markers (Runx2, alkaline phosphatase (Alk Phos), and osteocalcin (OC));
B, homeodomain proteins (DLX2, DLX3, and DLX5); and C, MSX2 and CDP/cut repressor proteins. Relative
mRNA expression levels of each gene at each time point were first normalized to glyceraldehyde-3-phosphate
dehydrogenase for control (BMP2) and BMP2-treated (BMP2) samples. The mRNA -fold induction levels
(BMP/BMP2) of n 3 assays per time point were plotted (mean S.D.).
MSX2/DLX3/DLX5 Regulation of Runx2 andOsteoblastogenesis
40518 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 52•DECEMBER 29, 2006
 at University of Southam
pton Libraries, on O
ctober 17, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
sion, 94 °C denaturation, 40 cycles). Amplicon specificity
was verified by analysis of melting temperature. All data
were collected during the linear phase of amplification.
Antibodies used for ChIP assays included the RUNX2
M-70 antibody (Santa Cruz Biotechnology). An affinity-pu-
rified polyclonal antibody was raised against a 16-amino acid
synthetic peptide (amino acids 242–256) of the murine
DLX3 protein as described previously (49). Mouse mono-
clonal MSX (1  2) antibody (4G1) against bacterially
expressed GallusMsx2 protein was obtained from Develop-
mental Studies Hybridoma Bank, Department of Biological
Sciences, University of Iowa. Affinity-purified polyclonal
DLX5 antibodies (Y20 and C20) were obtained from Santa
Cruz Biotechnology. Both anti-
bodies were raised against a
peptide mapping within an in-
ternal region (Y20) or the C ter-
minus (C20) of human DLX5.
Mouse monoclonal (clone
8WG16) RNA Pol II was purchased
from Covance Inc. Because the Msx
andDlx families sharemanycommon
sequences in addition to their DNA
binding domains, the specificities of
the different antisera obtained from
commercial sources used in these
studies were verified with in vitro
transcribed and translated HD pro-
teins (40).
RNA Interference—The mouse
MC3T3-E1 osteoblastic cells at
30–50% confluency were transfected
using Oligofectamine (Invitrogen)
with small interfering RNA (siRNA)
duplexes specific for murine Dlx3
obtained from Qiagen Inc. (Stanford,
CA) at different concentrations (50,
100, and 200 nM). The siRNA
duplexes were r(CCC UGU GUU
GCAAGUCGAA)dTdTandr(UUC
GAC UUG CAA CAC AGG G)
dAdG. For Dlx5, murine Dlx5-spe-
cific siRNA duplexes (siGENOME
SmARTpool reagent from Dharma-
con RNATechnologies) were used at
the same concentrations as that used
for Dlx3. To check the transfection
efficiency cells were also transfected
with siRNA duplexes specific for
green fluorescent protein. As a non-
specific control non-silencing siRNA
duplexes obtained from Qiagen Inc.
were used (sense, UUC UCC GAA
CGU GUC ACG UdT dT; antisense,
ACG UGA CAC GUU CGG AGA
AdT dT). Opti-MEM I (a reduced
serummedium from Invitrogen) was
used todilute the siRNAduplexesand
Oligofectamine and for transfection. After treating the cells with
siRNA for 4 h, the cells were supplementedwith-MEMcontain-
ing 30% fetal bovine serum for a final concentration of 10% in the
medium.The siRNAexperimentwas carried out for 72 h atwhich
time the cells were harvested for total protein andRNA to analyze
the knockdown effect of Dlx3 and Dlx5 siRNAs on endogenous
DLX3 and DLX5 expression on other osteoblast-specific markers
by real time qPCR.
RESULTS
Homeodomain Proteins Are Up-regulated at Different Stages
of BMP2-induced Osteogenesis in Vitro—The C2C12 mesen-
chymal cell culturemodel has been characterized for its respon-
FIGURE 2. Temporal expression of homeodomain proteins and osteoblast markers during growth and
differentiation of preosteoblast MC3T3 cells.MC3T3 cultures at the indicated days were harvested for the
isolation of total cellular RNA and analyzed by RT-qPCR with gene-specific primers (Table 1). The expression
values were normalized to glyceraldehyde-3-phosphate dehydrogenase values, and relative expression levels
of the specific gene against time were plotted. A, osteoblast markers Runx2 and osteocalcin; B, the distal-less
homeodomain proteins DLX3 and DLX5; C, Msh homeodomain protein MSX2 and CDP/cut.
FIGURE 3. Regulation of endogenous Runx2 by DLX3 comparedwith the other HD proteins. A, the 0.6-kb
Runx2 P1 promoter was co-transfected with MSX2, CDP/cut, DLX3, and DLX5 in NIH3T3 cells. The indicated
concentration range was evaluated to demonstrate potency of their effects on the Runx2 promoter. B, left
panel, inductionof endogenousRunx2mRNA (byRT-qPCR)mediatedbyDLX3andcomparedwithDLX5. Empty
vector (EV), 400 ng; DLX3/DLX5, 400 ng. The right panel shows nearly equivalent expression of DLX3 and DLX5
and the level of endogenous proteins by Western blot analysis.
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siveness to BMP2, expression of early response genes, and dif-
ferentiation into osteoblasts by microarray gene profiling (18,
50). Using this system, expression of HD proteins related to the
osteogenic process was confirmed by quantitative RT-PCR
(Fig. 1). As reported previously (18), we observed a reproducible
commitment point to osteogenesis that occurs 8 h after addi-
tion of BMP2 and is reflected by appearance of alkaline phos-
phatase expression, an early marker of bone formation (Fig.
1A). Runx2 is expressed in two waves reaching peak levels after
2 and 8 h. Osteocalcin, an osteoblast-specific marker, is signif-
icantly induced by 16 h.
Members of the distal-less family of homeodomain tran-
scription factors Dlx2 and Dlx3 are induced within 1–2 h of
BMP2 treatment and showed sustained expression (Fig. 1B). In
contrast, Dlx5 is clearly induced after the 8-h osteogenic com-
mitment point, and its level remains induced from 10- to
14-fold to the 24-h time point. The expression of two classical
repressor HD proteins are shown in Fig. 1C; Msx2 is rapidly
induced at 1 h (2–3-fold), whereas CDP/cut reaches peak
expression between 6 and 8 h. Thus homeodomain proteins
exhibit selective periods of induction and sustained gene
expression in the transition from premyogenic to the osteo-
genic phenotype.
To explore the biological significance of homeodomain pro-
tein expression patterns observed in the C2C12 BMP2-induced
osteogenic cell model, we examined BMP2 responsiveness of
these HD proteins in two mouse limb bud clonal cell lines that
were previously characterized for their osteogenic (clone 14) or
chondrogenic (clone 17) response to BMP2 (51, 52) (supple-
mental Fig. 1). For reference, the osteogenic markers alkaline
phosphatase and osteocalcin are clearly up-regulated in
response to BMP2 in clone 14 but not clone 17. Dlx2 was
responsive to BMP only in the chondrogenic line, whereas
Msx2,Dlx3, andDlx5were induced in both cell types. However,
CDP/cut interestingly was slightly down-regulated by BMP2 in
the osteogenic clone but up-regulated in the chondrogenic line.
These findings support the concept thatMSX and DLX class of
proteins are involved in BMP-mediated osteogenic or chondro-
genic pathways, whereas the CDP/cut protein is down-regu-
lated in osteoblasts, suggesting a function related to cartilage.
Dlx2 regulation by BMP2 in clone 17C is consistent with it role
in chondrogenesis (53).
DLX3 Is Continuously Up-regulated during Osteoblast
Differentiation—Because the BMP2-induced C2C12 model is
limited to commitment to osteogenesis and does not produce a
mineralizingmatrix, we examined the osteoprogenitorMC3T3
cell line that undergoes further differentiation to a mature
osteoblast (Fig. 2). These osteoprogenitors already express
Runx2 in the proliferation stage (Fig. 2A, day 7), but Runx2
levels were increased 40% by day 10 when cells are accumulat-
ing an extracellular matrix and have initiated cellular multilay-
ering. By day 10 osteocalcin expression, a marker of mature
osteoblasts, can be detected and is continuously up-regulated
(Fig. 2A). Interestingly Dlx5, which was not induced until after
the osteogenic commitment point in C2C12 cells, is expressed
in the proliferating MC3T3 osteoprogenitor cells and remains
at constitutive expression levels during differentiation.Dlx3,
however, is developmentally up-regulated 2–3-fold higher
during osteoblast differentiation. Both Msx2 and CDP/cut,
well characterized repressor transcription factors that sup-
press bone-specific genes (54, 55), were down-regulated at
the stages when mature osteoblast phenotypic markers are
expressed.
Molecular mechanisms that activate Runx2 expression are
poorly understood. The continuous up-regulation of Dlx3 and
Runx2 during MC3T3 osteoblast differentiation (Fig. 2) sug-
gests that Runx2 and Dlx3 expression are related. Indeed we
observed that the bone-related Runx2 P1 promoter is potently
stimulated by DLX3 (3–3.5-fold) in both NIH3T3 fibroblasts
and MC3T3 osteoblasts. Similar activation was observed with
promoter segments spanning 3- and 0.6-kb fragments (supple-
mental Fig. 2A). AWestern blot of the transfected cells demon-
strates comparable levels of HD protein expression in the two
cell types (supplemental Fig. 2B). Also for comparison, the
repressor activity of the MSX2 HD protein is shown to be sim-
ilar for both promoter fragments but less striking in the osteo-
blastic cells. These data sets demonstrate that DLX3 is a strong
activator of Runx2 gene expression and that the initial 0.6 kb of
the P1 promoter mediates the DLX response in both non-osse-
ous and bone cells.
DLX3 Is a Potent Activator of the Runx2Gene atMultiple HD
Regulatory Elements—To further appreciate the relative contri-
bution of DLX3 to regulation of Runx2 promoter activity in
relation to other homeodomain proteins, we examined activity
FIGURE 4. Dlx3 siRNA inhibits Runx2 gene expression in MC3T3 cells.
A, RNA interference effects of Dlx3 in MC3T3-E1 cells after 72 h of treatment
with either nonspecific (NS) or specific siRNA duplexes (described under
“Materials and Methods”) at the indicated doses. Left panel, the Western blot
of the cell lysate prepared from Dlx3 siRNA-treated MC3T3 cells probed with
anti-DLX3 and -RUNX2 antibodies. The Actin profile is shown for equal load-
ing of protein samples. The percent reduction for DLX3 and RUNX2 proteins
uponDlx3 siRNA treatmentwas quantitated by densitometry. The right panel
shows the expression profiles of Dlx3 and Runx2 (mRNA) by RT-qPCR in cells
treated with three doses of Dlx3 siRNA. B, RNA interference of Dlx5 in
MC3T3-E1 cells for comparison with Dlx3. The cells were treated with Dlx5-
specific SmARTpool siRNA for 72 h, and total cellular proteins and RNA were
isolated and analyzed. Left panel, Western blot probed with anti-DLX5,
-RUNX2, and -Actin antibodies with densitometric quantitation; right panel,
expression profiles by RT-qPCR of Dlx5 and Runx2.
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of the Runx2 P1 promoter as a function of HD protein concen-
tration comparing MSX2, DLX3, and DLX5 in MC3T3 cells in
which these HD proteins are developmentally expressed (Fig.
3). CDP/cut was less effective as a repressor of Runx2 promoter
activity than MSX2, whereas forced expression of DLX3 and
DLX5 increased promoter activity to approximately the same
extent. The increases in promoter activity by DLX3 and DLX5
are further reflected by endogenous Runx2 gene expression
determined byRT-qPCR (Fig. 3B). Twenty-four hours post-trans-
fection, we observed 2.5- and 2-fold increases in Runx2 by DLX3
and DLX5, respectively, inMC3T3 cells.
To provide additional evidence for DLX3 regulation of
Runx2, we tested the consequences of Dlx3 siRNA-mediated
depletion in MC3T3 cells (Fig. 4).
Dlx3 mRNA and protein were
reduced 50 and 80%, respectively, at
a 200 nMdosewith twoof threeDlx3
siRNAs (Fig. 4A, right panel, shows
the effect of one oligo). Runx2
mRNA at this dose was decreased
70%, and RUNX2 protein was
decreased by 62%. We also exam-
ined the inhibitory effects of Dlx5
siRNA duplexes on Runx2 expres-
sion (Fig. 4B). The Dlx5 siRNAs are
highly effective in decreasing Dlx5
mRNA cellular levels (by 75%), but
Runx2 expression was reduced to
48% at the 200 nM dose (Fig. 4B).
These results indicate that both
DLX3 and DLX5 are significant
enhancers of endogenous Runx2
gene expression in the osteopro-
genitor cells.
Our studies (Figs. 2 (supplemen-
tal) and 3) indicate that HDproteins
regulate the Runx2 gene through
the initial 0.6 kb of the P1 promoter.
This promoter segment contains
four HD consensus sequences (Fig.
5A). To address whether specific
DLX3- or DLX5-mediated activa-
tion occurs at multiple sites equiva-
lently or selectively, a series of pro-
moter deletion constructs were
examined (Fig. 5A). DLX3 and
DLX5 showed a similar stimulation
of Runx2 activity (2-fold) in the
600, 458, and 351 base pair
fragments (Fig. 5B). However, in
contrast to DLX3, DLX5-mediated
activation could be readily observed
for the288 and128 segments of
the promoter presumably because
of the higher affinity of DLX5 for
site D. To further examine this
observation of selective functional
activities as related to protein-DNA
interaction of the homeodomain protein at one of the regula-
tory sequences, gel shift studies (competition and antibody
supershift) were carried out (Fig. 5C). We find that recombi-
nant DLX3 and DLX5 bind site A/B (two overlapping
sequences) and site C to the same extent, but DLX5 bindsmore
strongly than DLX3 to site D. The combined results of protein-
DNA binding activity and deletion mutation studies demon-
strate that the Runx2 HD sites are responsive to DLX3 and
DLX5 and that differences in affinities for the Dlx consensus
motif may favor DLX5 binding to the proximal site D element.
Recruitment of Homeodomain Proteins to the Runx2 Gene at
Different Stages of Osteoblastogenesis—TheHDproteins exhib-
ited different expression profiles during development of the
FIGURE 5. Regulation of the Runx2 promoter activity bymultiple HD response elements. A, schematic
representation of regulatory elements in the Runx2 P1 promoter. Four putative homeodomain protein
binding sites are indicated: two overlapping HD sites (A/B) positioned from553 to564, site C (361 to
364), and site D (53 to56). Runx2 sites and purine-rich regions are indicated. Deletion mutations of
the Runx2 promoter upstream of the luciferase reporter gene (LUC) are indicated. Clone 458 contains two
downstream HD binding sites; clones351 to128 contain only one HD site. B, the deletion mutants of
Runx2 promoter-luciferase constructs (400g) were co-transfectedwith 200 ng of either backbone vector
(EV), DLX3, or DLX5 construct to study the HD responsiveness across the proximal Runx2 promoter. The
promoter activities were expressed in relative luciferase values for MC3T3 cells. All transfections were
performed in triplicate. Error bars represent n  6 mean  S.D. C, electrophoretic mobility shift assays
using 32P-labeled 20-bp probes representing each site with (control (C) or with in vitro transcribed and
translated (IVTT) proteins in the absence () or presence () of the respective antibody (Ab), DLX3 (left
panel) and DLX5 (right panel).
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osteoblast phenotype and like the Runx2 and osteocalcin genes
were temporally regulated during osteoblast differentiation
(Fig. 2). Therefore, we further characterized association of the
homeodomain proteins in primary calvaria-derived osteoblasts
that differentiate similarly to in vivo osteoblasts and produce a
mineralized bonelike nodule (56) (Fig. 6). HD protein levels
were monitored during the differentiation time course (Fig.
6B). Although Msx2 decreased, Runx2, Dlx3, and Dlx5
increased to maximal levels with formation of bone nodules
(day 12 in primary cells). Chromatin immunoprecipitation
studies were performed from the proliferation to differentia-
tion stages, selecting three time points: day 5, the proliferation
stage; day 12, the matrix maturation period; and day 20, the
mineralization stage. In these primary differentiating cells we
find a temporal recruitment ofHDproteins in relation toRunx2
transcription (Fig. 6C). We observed that only MSX2 is associ-
ated with Runx2 in the proliferation period (day 5). However,
MSX2 is no longer bound to Runx2 DNA by day 12 despite
significant cellular protein levels (Fig. 6B). On day 12 both
DLX3 and DLX5, as well as RUNX2, are recruited to the Runx2
FIGURE 6. In vivo occupancy of HD proteins in the proximal Runx2 promoter during osteoblast growth and differentiation. A, positions of the primers
used to amplify proximal Runx2 promoter in ChIP assays are indicated by arrows. B, cell layers from cultures of calvaria-derived primary rat osteoblasts were
harvestedat the indicateddays for homeodomainproteins, andRUNX2whichwereanalyzedbyWesternblot analysis. Profiles ofActinwereusedas a loading
control. C, formaldehyde-cross-linked soluble chromatin of primary calvarial osteoblasts harvested at days 5 (proliferation), 12 (matrix maturation), and 20
(mineralization) was immunoprecipitated with 3 g of the indicated antibodies. The DNA fragments from the immunocomplexes were purified and assayed
by PCRusing radioactive deoxynucleotides. Normal IgG (2g)was used as a control for each timepoint. Input represents 0.2%of each chromatin fraction used
for immunoprecipitation. ChIP data are representative of three experiments inwhich all three time pointswere derived from the same osteoblast preparation.
D, ChIP assays performed on primary calvarial osteoblasts harvested on days 4, 5, 6, and 7. DNA associated with the immunocomplexes of MSX2, DLX3, DLX5,
andPOL IIwaspurified andassayedasdescribed inC. E, DLX3protein-protein interactionswithMSX2andDLX5were examined inNIH3T3 cells transfectedwith
5gof taggedplasmid (Express-MSX2, Express-DLX5, andV5-DLX3)/100-mmplate. The lysateswere immunoprecipitatedwithMSX2,DLX3, andDLX5primary
antibodies and immunoblotted with antibodies against the V5 tag. F, summary of homeodomain protein expression and occupancy of factors on the Runx2
gene promoter at stages of osteoblast maturation. BMP2 induces a temporal expression of RUNX2 and HD during the differentiation of osteoprogenitors.
Illustrated in the top panels areHDprotein levels in primary osteoblasts. RUNX2 steadily increases during differentiation,whereasMSX2 andCDP/cut decrease,
andDLX3 andDLX5 exhibit peakmRNAexpression at distinct stages in primary osteoblasts (40). The lower panel shows recruitment of RUNX2 andHDproteins
to the Runx2 promoter at stages of osteoblast maturation that contribute to the bone-specific Runx2 promoter remodeling. Basal transcription is defined as
priming theRunx2promoter for gene activation, initially regulatedby the repressorHDproteinMSX2 (day 5) followedby inducerHDproteins, DLX3 transiently
(days 5 and 6), and DLX5 for optimal transcription. Themodel shows DLX5 associated with the proximal site (56/53) based on functional activity and DNA
binding (Fig. 5, B and C). RUNX2 provides autoregulation in mature osteoblasts. IP, immunoprecipitation; d, day.
MSX2/DLX3/DLX5 Regulation of Runx2 andOsteoblastogenesis
40522 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 52•DECEMBER 29, 2006
 at University of Southam
pton Libraries, on O
ctober 17, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
promoter (Fig. 6C). The preferential binding of Dlx5 in late
stages may be attributable to relatively higher affinity for Dlx
elements in the Runx2 promoter. However, we observed that
DLX3 association is transient in the immediate postprolifera-
tive stage of osteoblast maturation. On day 20, an increased
association of RUNX2 to its own promoter was also observed.
The increase in RUNX2 protein at this stage is associated with
the promoter (Fig. 6C), although a slight decrease in cellular
protein was observed (Fig. 6B). Thusmaintenance of RNAPOL
II bindingwould be consistent withRUNX2 autoregulation and
sustained transcription by DLX5.
To further define induced Runx2 transcription (after release
from MSX2 repression) by DLX3 and/or DLX5, ChIP studies
were performed at earlier time points from day 4 to day 8 (every
24 h). We find low amounts of MSX2 on the promoter on day
4 and no activating transcription factors, but RNA POL II is
present (Fig. 6D). By day 6 DLX3, DLX5, and RUNX2 are
recruited to the Runx2 gene concomitant with a 2-fold
increase in RNA POL II. By day 7 with robust Runx2 mRNA
(data not shown), a 12-fold increase in recruitment of these
factors is observed.
MSX2, DLX3, or DLX5 can form co-regulatory complexes
with RUNX2 that alter the transcriptional activity ofRunx2 (40,
57, 58). We therefore examined DLX3 interactions with MSX2
and DLX5 by co-immunoprecipitation in NIH3T3 cells trans-
fected with epitope-tagged expression constructs. DLX3 pref-
erentially formed complexes with DLX5 andMSX2 to different
degrees (Fig. 6E, lower panel). Thus recruitment of DLX3 to the
Runx2 promoter may occur as a direct protein-DNA interac-
tion or as aDLX3/DLX5heterodimer. Taken together, the tem-
poral profiles of HD protein expression in osteogenic cells
undergoing differentiation, their association with the Runx2
promoter, and their ability to form DLX3/DLX5 heterodimers
through protein-protein interactions are consistent with a
model in which homeodomain protein combinations tightly
regulate Runx2 gene expression to support osteoblast differen-
tiation (summarized in Fig. 6F).
DLX3 and DLX5 Promote Osteoblast Differentiation Inde-
pendently of Runx2 Activation—DLX3 and DLX5 are clearly
upstream regulators of Runx2, raising the question as to
whether their osteogenic effects are solely dependent on
RUNX2. To determine the potency of DLX3 and DLX5 in
mediating BMP2 bone forming properties in the absence of
RUNX2, we examined their ability to activate osteoblast-re-
lated genes in a Runx2 null cell line. We immortalized calvarial
cells from embryonic age E17.5 null mice (2, 62) (Fig. 7A). As a
control for these experiments, the effect of DLX3 and DLX5 on
Runx2mRNAwas quantitated by RT-qPCR. In this study, cells
were not treated with BMP2, and thus the induction of gene
expression represents the Runx2 mRNA mediated by the HD
proteins that were exogenously expressed. Runx2 mRNA is
induced 2-fold in this cell line (Fig. 7B), although no functional
RUNX2 protein is translated (data not shown). Runx2 null cells
were transfected with either RUNX2, DLX3, or DLX5 and
DLX3 or DLX5 in combination with RUNX2 (Fig. 7C shows
plasmid expression levels). Expression of two osteoblast mark-
ers was quantitated in total cellular RNAby RT-qPCR (Fig. 7C).
Alkaline phosphatase, an earlier marker of osteoblast differen-
tiation, is up-regulated by DLX3 and DLX5 to the same extent
as RUNX2.However, in the presence of exogenous RUNX2 and
HD protein, a modest suppression of alkaline phosphatase
expressionmediated byDLX3 andDLX5 is observed. This find-
ing is consistent with the known down-regulation of alkaline
phosphatase in more mature osteoblasts. Osteocalcin (OCN), a
marker of mature osteoblasts, was induced 5-fold by RUNX2,
3.8-fold by DLX3, and 4.5-fold by DLX5. We also observed an
induction of collagen type 12 (Col 12) chain but not the Col
11 subunit by DLX3 andDLX5 (supplemental Fig. 3). RUNX2
had no significant effect on expression of either Col 11 or Col
12 genes. The addition of RUNX2 had only amodest effect on
the activationmediated by theHDproteins. These studies show
that DLX3 and DLX5 can induce expression of osteogenic
genes independently of RUNX2 and that both DLX proteins
have the same potency as RUNX2. These findings of direct reg-
ulation of osteoblast genes provide mechanistic insight for ear-
lier observations that BMP2 induced alkaline phosphatase and
osteocalcin in primary calvarial cells from the Cbfa1 (Runx2)
null mouse (2). Thus the HD pathways contribute to control of
osteoblast genes for bone formation independently of RUNX2
as well as through RUNX2 (Fig. 7D).
DISCUSSION
MSX and DLX homeodomain proteins have unique and
coordinated roles in patterning and initiating formation of skel-
etal structures during embryogenesis prior to the onset of bone
tissue formation. Here we have identified a molecular mecha-
nism by which homeodomain proteins contribute to osteoblast
differentiation and bone formation through regulation of the
RUNX2 transcription factor, a requirement for in vivo bone
formation. Our findings identify DLX3 for the first time as a
significant regulator of Runx2 gene expression at an early stage
of osteoblastmaturation.We further show thatDLX3, aswell as
DLX5, is competent to promote expression of osteoblast genes
in Runx2 null cells, thus demonstrating that DLX3 and DLX5
can mediate osteoblast differentiation in a RUNX2-independ-
entmanner. Our combined results show (i) transcriptional reg-
ulation ofRunx2 byDLX3,MSX2, andDLX5mediated through
multiple responsive elements in the bone-specific P1 promoter,
(ii) temporal expression patterns of HD proteins in cell models
and in primary calvarial cells during differentiation, (iii) func-
tional activities of HD proteins by overexpression and knock-
down studies, and (iv) recruitment of HDproteins to theRunx2
gene during osteoblast differentiation. These results together
support our conclusion that DLX3, like DLX5 (37), is a key
transactivator of Runx2 gene expression. DLX3 appears to reg-
ulate Runx2 at early stages of osteoblastogenesis, whereas
DLX5 functions later.
We have previously shown that the knockdown of Dlx3
results in a block of osteoblast maturation of MC3T3-E1 cells
by inhibiting expression of HD-regulated phenotypic genes,
including collagen type I, osteopontin, bone sialoprotein, and
osteocalcin (40). Now that we have demonstrated that DLX3
up-regulates Runx2 promoter activity in a segment of the pro-
moter that lacks a BMP/SMADresponse element, a linear path-
way from BMP2 to DLX3 to Runx2 is defined. Our finding that
DLX3, as well as DLX5, can regulate Runx2 and RUNX2 target
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genes in the absence of RUNX2 provides additional evidence
for a regulatory pathway from BMP2 to commitment to osteo-
genesis via Dlx3 gene regulation. The present studies provide
evidence that a mechanism contributing to the roles of both
DLX3 and DLX5 in bone formation is through activation of
Runx2. However, DLX3 and DLX5 regulate Runx2 at different
stages of osteogenic differentiation. The contribution of both
DLX3 and DLX5 proteins to the regulation of osteoblastogen-
esis via control of Runx2 is consistent with in vivo studies of
Dlx5 null mice (59) in which normal expression levels of Runx2
are observed possibly due to compensation by DLX3. Runx2
andDlx3 exhibit similar profiles of expression (bothmRNAand
protein) during early differentiation of BMP2-treated C2C12
cells (1–6 h), in mouseMC3T3 cells, and in primary rat calvar-
ial osteoblasts. In contrast,Dlx5 is induced after the osteogenic
commitment point (at 8 h) in C2C12 cells. In primary calvarial
osteoblasts robust Dlx3 expression also precedes Dlx5 during
differentiation. Thus, DLX3 appears to have a very specialized
transient role in activating osteogenic genes at early stages of
differentiation.
The significance of transcriptional regulation of Runx2 by
multiple HD response elements that bind both the repressor
and activator HD proteins is underscored by two complemen-
tary observations: 1) the temporal expression profiles in
response to BMP2 and during osteoblast differentiation and 2)
the temporal recruitment and displacement of HD proteins on
the Runx2 promoter related to stages of osteoblast maturation.
RUNX2 cellular levels need to be precisely regulated with
expression supporting lineage direction in osteoprogenitor
cells (60) and up-regulated levels promoting differentiation (12,
15). There appears to be a requirement for multiple HD
sequences to regulate both the repressor and enhancer activi-
ties of different classes of HD proteins that recognize the core
consensus 5-TAATmotif (this study and Ref. 37). The roles of
the repressor MSX2 and enhancer DLX proteins in postnatal
bone formation and osteoblast differentiation involve several lev-
els of transcriptional control. Affinities for protein-DNA binding
in the context of promoter sequences, cellular levels of the pro-
teins, and formation of HD heterodimeric complexes all con-
tribute to positive and negative regulation of Runx2 that sup-
ports fine tuning of gene expression for physiological control of
osteoblast differentiation. We have shown here that DLX3
interacts with DLX5 in addition to the HD protein-RUNX2
interactions reported previously (40, 58, 61). Thus formation of
these protein-protein complexes may influence transcription
by either preventing DNA binding or modifying activity of a
DNA-bound complex.
Our chromatin immunoprecipitation studies reveal a tempo-
ral recruitment of MSX2 and the DLX3/DLX5 proteins to the
Runx2 gene during differentiation of primary osteogenic cells.
We find exclusive association of MSX2 with the Runx2 gene in
the proliferation period when Runx2 expression is minimally
detected. These results are consistent with strong repression of
Runx2 promoter activity byMSX2 (our results) andwithMSX2
tissue distribution (24, 37). MSX2 may function to prime the
promoter for transcription by interaction with the phosphoryl-
ated POL II-associated transcription factor IIF (TF11F). Towler
and co-workers (58) demonstrated that MSX2-mediated
repression of the osteocalcin gene promoter can be overcome
more than 50% by overexpression of TFIIF in mouse osteo-
blasts. A molecular switch occurs postproliferatively with loss
of MSX2 and appearance of DLX3, DLX5, and Runx2 at the
promoter with increased Pol II. However, DLX3 association
with the Runx2 promoter is transient, whereas DLX5 remains
bound to Runx2 in mature osteoblasts (day 20, mineralized
matrix). The increased occupancy of RUNX2 to its own pro-
moter from day 12 to day 20 and the decreased total cellular
RUNX2 protein on day 20 are consistent with RUNX2 recruit-
ment to its own promoter for autoregulation (45). Although
RUNX2 autoregulates its transcription on day 20, the simulta-
neous increased association of DLX5 further supports the role
of DLX5 as an activator at later stages of differentiation. This
finding is consistent with in vitro studies (37). Thus, the HD
FIGURE 7. Evidence for DLX3 and DLX5 promoting osteogenic differenti-
ation independent of Runx2. Runx2 immortalized null cells were trans-
fected with 200 g of either RUNX2, DLX3, DLX5, or both RUNX2 and one of
theHDexpressionvectors. Cellswere collectedafter 24h for total cellular RNA
and protein isolation. The expression of osteogenic marker genes was quan-
titatedbyqPCR.A, schematic of the targetedRunx2gene innull cells.B, induc-
tion of Runx2 mRNA by DLX3 and DLX5 in the Runx2 null cells, although no
protein is translated by Western blot analyses (data not shown). C, upper
panel, Western analyses of RUNX2 and HD protein expression levels in cell
lysates 24h after transfection. Lower panel, activationof alkaline phosphatase
(ALP) and inductionofosteocalcin (OCN) byRUNX2,DLX3, andDLX5by recon-
stituting the Runx2 null cells with Runx2. D, summary of BMP2 regulatory
network for regulation of osteogenesis. As an early event of the BMP2 osteo-
genic induction pathway, Smad signaling and HD proteins are activated; this
will induce Runx2 expression, and these factors can regulate target genes.
There is evidence that formation of RUNX2-SMAD complexes is a critical
mediator of osteogenesis. In the absence of RUNX2, DLX3 and DLX5 can con-
tribute to osteogenesis through regulation of osteoblast-related genes (5, 6,
61). K/O, knock-out; EV, empty vector;OC, osteocalcin; BSP, bone sialoprotein;
NEO, neomycin.
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network along with Runx2 promoter autoregulation assures
optimal physiologic regulation of RUNX2 expression inmature
osteoblasts.
In conclusion, our findings suggest a very specific mecha-
nism for regulating Runx2 transcription by switching from
MSX2 occupancy to DLX3 and then DLX5 occupancy of the
Runx2 promoter. We first observed this molecular switch on
the osteocalcin gene promoter, which it was mediated through
only the HD regulatory element, the tissue-specific osteocalcin
box (40). Our findings of the temporal recruitment of the HD
proteins to regulate Runx2 transcription during osteoblast dif-
ferentiation reveal a regulatory network of HD protein gene
regulation operative on the Runx2 promoter. Equally impor-
tant, our results demonstrate that both DLX3 and DLX5 con-
tribute to RUNX2-dependent and -independent regulation of
osteogenic genes. These findings establish a novel BMP2
response pathway in which homeodomain proteins act both
upstream of and parallel to RUNX2 to promote osteogenesis
with further convergence of the BMP2 osteogenic signal
through RUNX2-SMAD interactions (5, 6) and RUNX2-home-
odomain interactions (40, 57, 58, 61).
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